2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4484 Real world analysis of anti-CD19 CART for marginal zone lymphoma

Zachary Hunzeker, MD, Nima Ghalehsari, MD2, Lei Feng, MS3, Daria Potapova4, Madiha Iqbal, MBBS, MD5, Arvin Eslami, MD6, Yun Kyoung Tiger, MD, PhD7, Jose Sandoval-Sus I, MD8, Sean Haney, MD9, Samuel Yamshon, MD10, Saurabh Dahiya, MD11, Yucai Wang, MD, PhD12, Caron Jacobson, MD, MMSc13, Michael D. Jain, MD, PhD14, Paolo Strati, MD15
1 University of Texas MD Anderson Cancer Center, Houston, United States
2 Moffitt Cancer Center, Tampa, United States
3 University of Texas MD Anderson Cancer Center, Houston, United States
4 Dana Farber Cancer Institute, Boston, United States
5 Mayo Clinic, Rochester, United States
6 Stanford Cancer Institute, Palo Alto, United States
7 Mayo Clinic, Rochester, United States
8 Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, United States
9 Moffitt Cancer Center, Tampa, United States
10 New York University Langone Health Perlmutter Cancer Center, New York City, United States
11 Stanford Cancer Institute, Palo Alto, United States
12 Mayo Clinic, Rochester, United States
13 Dana Farber Cancer Institute, Boston, United States
14 Moffitt Cancer Center, Tampa, United States
15 University of Texas MD Anderson Cancer Center, Houston, United States

Background: The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) was approved by the FDA for adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) after 2 or more lines of systemic therapy in 2025, based on the phase 2 TRANSCEND-FL trial (67 patients). Axicabtagene ciloleucel (axi-cel) has been indicated in the NCCN guidelines as a treatment option for the same population since 2022, based on the phase 2 ZUMA-5 trial (31 patients), which excluded patients with splenic MZL (SMZL).

In these trials, liso-cel demonstrated an overall response rate (ORR) of 95% and complete response (CR) rate of 62% with grade (G) ≥3 cytokine release syndrome (CRS) and immune cell associated neurotoxicity syndrome (ICANS) occurring in 4% of patients each. Axi-cel led to an ORR of 77% and CR rate of 65%, with G≥3 CRS and ICANS occurring in 8% and 33% of patients, respectively.

No real-world experience of these products in patients with MZL has been described to date.

 

Methods: This is a retrospective multi-center study of patients with R/R MZL who received commercial axi-cel or liso-cel across 8 academic sites from January 2022 through March 2026, with a data cutoff for follow-up of July 2026. Patients who received axi-cel or liso-cel on clinical trials were excluded. Baseline characteristics were collected before initiation of lymphodepleting chemotherapy. CRS and ICANS were prospectively graded according to ASTCT criteria. Response was prospectively assessed by Lugano 2014 Criteria. Baseline characteristics and outcomes were summarized using descriptive statistics. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier (KM) method. Follow-up time was estimated by reverse KM.

 

Results: Twenty-four patients were included in the analysis: 15 (63%) received axi-cel and 9 (38%) received liso-cel, after a median of 4 (range 2-7) prior lines of systemic therapy, including bendamustine in 17 (71%). The median age was 66 years (range 46-78), 12 (50%) were male, and 3 (13%) patients had ECOG performance status of 2. Nine (38%) patients had nodal MZL (NMZL), 9 (38%) extra-nodal MZL (EMZL), and 6 (25%) SMZL. Twenty (83%) patients had advanced stage disease, including 12 (50%) with bone marrow involvement and 2 (8%) with peripheral blood involvement. Nine (40%) were refractory to last line of treatment; 15 (60%) had relapsed. Eight (33%) had a baseline LDH above upper limit of normal, 1 (4%) had creatinine >1.5 mg/dL, 5 (21%) had grade ≥3 cytopenias, 1 (4%) had active infection with fungal sinusitis, 2 (8%) had clinically significant pleural effusions, and 1 (4%) had autoimmune disease requiring systemic immunosuppression. In all, 6 (25%) patients would have been ineligible for TRANSFORM-FL and 15 (63%) would have been ineligible for ZUMA-5.

Ten (42%) patients received bridging therapy (BT): systemic therapy alone in 8 (33%), radiation alone in 1 (4%), and both in 1 (4%); 6 of the 9 receiving systemic BT received Bruton tyrosine kinase inhibitors. Twenty-one (88%) patients developed CRS of any grade (100% of axi-cel vs 67% of liso-cel recipients), with G3-4 in 3 (13%) patients (20% of axi-cel vs 0% of liso-cel recipients); ICANS of any grade occurred in 12 (50%) patients (67% of axi-cel vs 22% of liso-cel recipients), with G3-4 in 3 (13%) patients (20% of axi-cel vs 0% liso-cel recipients). Day 30 G3-4 cytopenia was observed in 29% of patients, with infections also in 29% by Day 30. No G5 CRS or ICANS events occurred.

Two patients died, one from progression-related intracranial hemorrhage and one from undetermined cause after achieving a day 30 CR. Among all patients, the day 30 ORR was 92% and CR rate was 83%. Median PFS was not reached after a median follow-up of 12.4 months (95% confidence interval [CI], 6.3-24.2 months). The 12-month PFS rate was 83.1% (95% CI 66.8-100%) and 12-month OS rate was 90.7% (95% CI 79.2-100%), with no further deaths after the two early events.


Conclusion
: This retrospective multi-center study demonstrates for the first time that liso-cel and axi-cel are feasible and effective for R/R MZL in a real-world setting, including patients who would not have met eligibility criteria in pivotal trials. Additional patients are being analyzed, and a larger, updated dataset will be presented at the upcoming meeting.

Zachary Hunzeker, MD: No relevant conflicts of interest to declare.